IDEXX Laboratories, Inc.

Equities

IDXX

US45168D1046

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 04:00:00 2024-09-19 pm EDT 5-day change 1st Jan Change
517.06 USD +1.13% Intraday chart for IDEXX Laboratories, Inc. +4.03% -6.84%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
IDEXX Laboratories, Inc. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-04-2024 11:30 AM
IDEXX Laboratories, Inc. - Analyst/Investor Day
Piper Sandler Adjusts Price Target on IDEXX Laboratories to $520 From $600 MT
BNP Paribas Exane Adjusts Price Target on IDEXX Laboratories to $607 From $641 MT
Tranche Update on IDEXX Laboratories, Inc.'s Equity Buyback Plan announced on August 13, 1999. CI
IDEXX Laboratories, Inc., Q2 2024 Earnings Call, Aug 06, 2024
IDEXX Labs cuts annual forecast as vet visits remain slow RE
IDEXX Laboratories Q2 Adjusted Earnings, Revenue Rise; Lowers 2024 Revenue Guidance MT
Earnings Flash (IDXX) IDEXX LABORATORIES Reports Q2 Revenue $1B, vs. Street Est of $1B MT
IDEXX Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 CI
IDEXX Laboratories, Inc. Revises Earnings Guidance for the Year 2024 CI
BTIG Starts IDEXX Laboratories With Buy Rating, $580 Price Target MT
Morgan Stanley Adjusts Price Target on IDEXX Laboratories to $589 From $596, Maintains Overweight Rating MT
Stifel Adjusts Price Target on IDEXX Laboratories to $510 From $520 MT
IDEXX Laboratories, Inc. Presents at Stifel Jaws & Paws Conference, May-29-2024 10:55 AM
Morgan Stanley Adjusts Price Target on IDEXX Laboratories to $596 From $620 MT
BNP Paribas Adjusts Price Target on IDEXX Laboratories to $641 From $653 MT
Goldman Sachs Adjusts Price Target on IDEXX Laboratories to $600 From $675 MT
Stifel Adjusts Price Target on IDEXX Laboratories to $520 From $570 MT
Barclays Adjusts Price Target on IDEXX Laboratories to $570 From $655 MT
Redburn Atlantic Adjusts Price Target on IDEXX Laboratories to $500 From $460 MT
Wall Street: heaviness prevails after a volatile episode CF
Tranche Update on IDEXX Laboratories, Inc.'s Equity Buyback Plan announced on August 13, 1999. CI
IDEXX Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
IDEXX Laboratories, Inc., Q1 2024 Earnings Call, May 01, 2024
Chart IDEXX Laboratories, Inc.
More charts
Logo IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc. is a world leader in the design, development and marketing of diagnostic test instruments for animal health monitoring and analysis of dairy products and water. Net sales break down by area of application as follows: - veterinary diagnoses for pets (91.6%); - water quality analysis (4.6%); - veterinary diagnoses for livestock and poultry (3.3%): solutions that help detect infectious diseases in ruminants, pigs, poultry and horses. The group also offers test solutions for dairy products; - other (0.5%). Net sales by source of income break down between product sales (57.1%) and services (42.9%). Net sales are distributed geographically as follows: the United States (65.3%), Canada (4.1%), Americas (2.3%), Germany (4.1%), the United Kingdom (3.3%), France (2.7%), Italy (1.5%), Spain (1.4%), Switzerland (0.9%), the Netherlands (0.8%), Europe/Middle East/Africa (4.8%), Australia (2.6%), Japan (2.1%), China (1.2%) and Asia/Pacific (2.9%).
Employees
11,000
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
517.06USD
Average target price
546.78USD
Spread / Average Target
+5.75%
Consensus
  1. Stock Market
  2. Equities
  3. IDXX Stock
  4. News IDEXX Laboratories, Inc.
  5. Redburn Atlantic Adjusts Price Target on IDEXX Laboratories to $500 From $460